Driehaus reduces holding in Crinetics Pharmaceuticals (NASDAQ: CRNX) to 6.11%

Rhea-AI Filing Summary

Driehaus Capital Management LLC amends its Schedule 13G/A to report beneficial ownership of Crinetics Pharmaceuticals common stock. As of March 31, 2026, Driehaus held 6,395,922 shares, representing 6.11% of the class, down from 7.54% as of December 31, 2023. The filing states these shares are held on a fully discretionary basis for multiple clients and that voting and dispositive power is shared by Driehaus. The amendment was signed on May 15, 2026.

Insights

Institutional Ownership Analyst

Institutional stake trimmed to 6.11% as of March 31, 2026.

Driehaus reports 6,395,922 shares beneficially owned, with shared voting and dispositive power, held across numerous client accounts. The filing clarifies that ownership is managed on a fully discretionary basis and that no single disclosed client holds over 5%.

This amendment records a lower percentage than the prior 12/31/2023 figure of 7.54%; subsequent activity or client account flows likely drove the change. Future filings may show further position adjustments.

Corporate Governance Specialist

Filing emphasizes shared authority and discretionary management.

The report states Driehaus has shared voting and shared dispositive power over the reported shares, indicating voting decisions may be coordinated across client accounts under DCM's management. The Form 13G/A format signals passive investor status rather than an activist intent.

Investors should note the filing attributes holdings to client accounts rather than a single beneficial owner; disclosures assert no client holds the referenced shares with rights to more than 5%.

Key Figures

Beneficially owned shares: 6,395,922 shares Percent of class: 6.11% Prior reported percent: 7.54% +3 more

6 metrics

Beneficially owned shares 6,395,922 shares Amount beneficially owned as of March 31, 2026

Percent of class 6.11% Ownership percentage as of March 31, 2026

Prior reported percent 7.54% Ownership percentage as of December 31, 2023

Sole voting power 0 Sole power to vote reported in Item 4

Shared voting power 6,395,922 Shared voting power reported in Item 4

Signed date May 15, 2026 Signature date on the amendment

Key Terms

Schedule 13G/A, beneficially owned, shared dispositive power, fully discretionary basis

4 terms

Schedule 13G/A regulatory

"This amendment is filed to reflect the change in our percentage of ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Amount beneficially owned: 6395922"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 6,395,922.00"

fully discretionary basis financial

"held by numerous clients on a fully discretionary basis"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 07:08 AM Learn about SEC filing dates

FAQ

What stake does Driehaus hold in Crinetics Pharmaceuticals (CRNX)?

Driehaus reported beneficial ownership of 6,395,922 shares, equal to 6.11% of Crinetics common stock as of March 31, 2026. The filing is an amended Schedule 13G/A reflecting the updated percentage.

How does this filing describe voting and disposition rights?

The filing states Driehaus has shared voting power and shared dispositive power over the reported shares, with no sole voting or sole dispositive power claimed in the amendment.

Did Driehaus increase or decrease its ownership since the prior disclosure?

The amendment notes ownership declined from 7.54% as of December 31, 2023 to 6.11% as of March 31, 2026, reflecting a reduction in percentage ownership reported by Driehaus.

Are the reported shares held on behalf of a single client?

No; the filing explains the shares are held across numerous client accounts managed by Driehaus on a fully discretionary basis and states no single client is known to have rights to over 5% of the class.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Crinetics Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

22663K107

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 22663K107

1

Names of Reporting Persons

DRIEHAUS CAPITAL MANAGEMENT LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,395,922.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,395,922.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,395,922.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.11 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: This amendment is filed to reflect the change in our percentage of ownership of Crinetics Pharmaceuticals, Inc. (CRNX). DCM owned 6.11% of CRNX as of March 31, 2026, down from 7.54% as of December 31, 2023.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Crinetics Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 10222 Barnes Canyon Road, Bldg, 2, San Diego, CA 92121
Item 2.
(a)	Name of person filing: Driehaus Capital Management LLC
(b)	Address or principal business office or, if none, residence: 25 East Erie Street Chicago, IL 60611
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 22663K107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6395922
(b)	Percent of class: 6.11%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 6395922
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 6395922
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The shares reported by Driehaus Capital Management LLC (DCM) are held by numerous clients on a fully discretionary basis in accounts managed by DCM. Securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power. To the best of DCM's knowledge, none of the referenced clients have the right to receive dividends or direct proceeds from the sale of interests relating to more than 5% of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DRIEHAUS CAPITAL MANAGEMENT LLC

Signature:	Janet McWilliams
Name/Title:	General Counsel
Date:	05/15/2026